



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Radiology

ESPS Manuscript NO: 8386

Title: Utility of additional GSA-SPECT information to CT based dose volume histogram in the radiotherapy for advanced hepatocellular carcinoma with liver cirrhosis

Reviewer code: 00036624

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-12-28 14:37

Date reviewed: 2013-12-30 19:44

| CLASSIFICATION | LANGUAGE EVALUATION | RECOMMENDATION | CONCLUSION |
|--|--|-------------------------------------|--|
| <input type="checkbox"/> Grade A (Excellent) | <input type="checkbox"/> Grade A: Priority Publishing | Google Search: | <input type="checkbox"/> Accept |
| <input type="checkbox"/> Grade B (Very good) | <input type="checkbox"/> Grade B: minor language polishing | <input type="checkbox"/> Existed | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C (Good) | <input type="checkbox"/> Grade C: a great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection |
| <input type="checkbox"/> Grade D (Fair) | <input type="checkbox"/> Grade D: rejected | <input type="checkbox"/> Existed | <input type="checkbox"/> Minor revision |
| <input type="checkbox"/> Grade E (Poor) | | <input type="checkbox"/> No records | <input type="checkbox"/> Major revision |

COMMENTS TO AUTHORS

The paper is of great interest as it depicts a new RT technique/planning for HCC treatment with good 2 years survival in advanced disease. Unfortunately, the paper results reader-unfriendly and necessitates a thorough language revision by a mother tongue, before it can be considered for review.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Radiology

ESPS Manuscript NO: 8386

Title: Utility of additional GSA-SPECT information to CT based dose volume histogram in the radiotherapy for advanced hepatocellular carcinoma with liver cirrhosis

Reviewer code: 00289524

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-12-28 14:37

Date reviewed: 2014-01-27 05:18

| CLASSIFICATION | LANGUAGE EVALUATION | RECOMMENDATION | CONCLUSION |
|--|--|-------------------------------------|--|
| <input type="checkbox"/> Grade A (Excellent) | <input type="checkbox"/> Grade A: Priority Publishing | Google Search: | <input type="checkbox"/> Accept |
| <input type="checkbox"/> Grade B (Very good) | <input type="checkbox"/> Grade B: minor language polishing | <input type="checkbox"/> Existed | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C (Good) | <input type="checkbox"/> Grade C: a great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection |
| <input type="checkbox"/> Grade D (Fair) | <input type="checkbox"/> Grade D: rejected | <input type="checkbox"/> Existed | <input type="checkbox"/> Minor revision |
| <input type="checkbox"/> Grade E (Poor) | | <input type="checkbox"/> No records | <input type="checkbox"/> Major revision |

COMMENTS TO AUTHORS

It is an interesting and useful study. However, there are issues with the way the manuscript has been composed. It will require improvement in grammar and sentence structures before it can be accepted.

ESPS Peer-review Report

Name of Journal: World Journal of Radiology

ESPS Manuscript NO: 8386

Title: Utility of additional GSA-SPECT information to CT based dose volume histogram in the radiotherapy for advanced hepatocellular carcinoma with liver cirrhosis

Reviewer code: 02353682

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-12-28 14:37

Date reviewed: 2014-02-09 02:00

| CLASSIFICATION | LANGUAGE EVALUATION | RECOMMENDATION | CONCLUSION |
|--|---|-------------------------------------|--|
| <input type="checkbox"/> Grade A (Excellent) | <input type="checkbox"/> Grade A: Priority Publishing | Google Search: | <input type="checkbox"/> Accept |
| <input type="checkbox"/> Grade B (Very good) | <input checked="" type="checkbox"/> Grade B: minor language polishing | <input type="checkbox"/> Existed | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C (Good) | <input type="checkbox"/> Grade C: a great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection |
| <input checked="" type="checkbox"/> Grade D (Fair) | <input type="checkbox"/> Grade D: rejected | BPG Search: | <input type="checkbox"/> Minor revision |
| <input type="checkbox"/> Grade E (Poor) | | <input type="checkbox"/> Existed | <input checked="" type="checkbox"/> Major revision |
| | | <input type="checkbox"/> No records | |

COMMENTS TO AUTHORS

I was quite confusing the way the paragraphs were listed to build up the review. Why did the Authors begin with combination therapy with TACE instead of details of the technique? In my opinion, after the introduction, methods should follow and thereafter the results in HCC subpopulations should be listed. In addition I would be pleased to read more about clinical selection of these patients; for example were the patient excluded from systemic therapy with Sorafenib and why? Another unclear point: how many patients in each HCC subgroup have been treated with this method?. More information about costs would be welcome